Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5731-5734

  Riely, Gregory J ^a,d   Kris, Mark G ^a   Rosenbaum, Daniel ^a   Marks, Jenifer ^a   Li, Allan ^b   Chitale, Dhananjay A ^b   Nafa, Khedoudja ^b   Riedel, Elyn R ^d   Hsu, Meier ^d   Pao, William ^a,c   Miller, Vincent A ^a   Ladanyi, Marc ^b,c  

^a Thoracic Service   (United States)

^b Department of Pathology ^*

^c Human Oncology and Pathogenesis Program   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CIGARETTE SMOKING; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ADENOCARCINOMA; ADULT; AGED; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SMOKING;

EID: 53249145767     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0646     Document Type: Article

References (24)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N EnglJ Med 2004;350:2129-39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. PaoW, MillerV, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
4. Pham D, Kris MG, Riely GJ, et al. Use of cigarettesmoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006;24:1700-4.
5. Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007;25:2248-55.
6. Kris MG, Pao W, Zakowski M, et al. Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. 2006 ASCO Annual Meeting; 2006; Atlanta (GA): Am Soc Clin Oncol; 2006. p. 369s.
7. Sequist LV, Martins RG, Spigel D, et al. Fine-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
8. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-35.
9. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006;119:2586-91.
10. Suzuki M, Shigematsu H, lizasa T, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006;106: 2200-7.
11. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999;17: 668-75.
12. Slebos R, Kibbelaar R, Dalesio O. K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. N EnglJ Med 1990;323:561-5.
13. Rosell R, Molina F, Moreno I, et al. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 1995; 12Suppl1:S59-70.
14. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected nonsmall-cell lung cancer. N Engl J Med 2005;352: 2589-97.
15. Pao W. Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
16. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-30.
17. Hainaut P, Pfeifer GP. Patterns of p53 G to T transversions in lung cancer reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
18. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-8.
19. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-7.
20. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
21. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64: 8919-23.
22. Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 1994;59: 494-504.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55: 74-108.
24. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-70. 25. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7: 778-90.